PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $152,071,709 | -23.4% | 4,956,705 | +0.1% | 0.00% | -20.0% |
| Q2 2023 | $198,439,142 | -2.3% | 4,952,312 | -0.5% | 0.01% | 0.0% |
| Q1 2023 | $203,161,077 | +6.8% | 4,978,218 | +1.1% | 0.01% | 0.0% |
| Q4 2022 | $190,161,779 | -26.6% | 4,925,195 | +1.2% | 0.01% | -37.5% |
| Q3 2022 | $258,953,000 | -7.7% | 4,868,445 | +1.1% | 0.01% | 0.0% |
| Q2 2022 | $280,613,000 | -21.6% | 4,813,257 | +2.7% | 0.01% | 0.0% |
| Q1 2022 | $357,797,000 | +27.4% | 4,688,119 | +0.5% | 0.01% | +33.3% |
| Q4 2021 | $280,751,000 | +5.1% | 4,665,955 | -2.1% | 0.01% | -14.3% |
| Q3 2021 | $267,012,000 | -6.9% | 4,768,063 | +0.9% | 0.01% | 0.0% |
| Q2 2021 | $286,709,000 | -9.2% | 4,724,929 | +4.8% | 0.01% | -22.2% |
| Q1 2021 | $315,863,000 | +20.9% | 4,506,531 | +3.2% | 0.01% | +12.5% |
| Q4 2020 | $261,337,000 | +1.4% | 4,367,266 | +1.8% | 0.01% | -11.1% |
| Q3 2020 | $257,821,000 | +12.3% | 4,288,443 | -2.0% | 0.01% | +12.5% |
| Q2 2020 | $229,609,000 | +56.8% | 4,375,979 | +0.2% | 0.01% | +33.3% |
| Q1 2020 | $146,420,000 | -25.6% | 4,366,819 | +0.5% | 0.01% | -14.3% |
| Q4 2019 | $196,808,000 | +16.6% | 4,344,554 | -2.0% | 0.01% | +16.7% |
| Q3 2019 | $168,719,000 | -1.3% | 4,431,828 | +12.8% | 0.01% | 0.0% |
| Q2 2019 | $170,891,000 | +14.5% | 3,929,411 | +0.2% | 0.01% | 0.0% |
| Q1 2019 | $149,251,000 | -8.3% | 3,921,465 | +3.6% | 0.01% | -14.3% |
| Q4 2018 | $162,837,000 | -9.0% | 3,785,145 | +3.9% | 0.01% | 0.0% |
| Q3 2018 | $178,976,000 | +64.3% | 3,641,417 | +7.2% | 0.01% | +40.0% |
| Q2 2018 | $108,913,000 | +6.5% | 3,398,204 | +3.5% | 0.01% | +25.0% |
| Q1 2018 | $102,279,000 | -31.1% | 3,283,448 | +0.9% | 0.00% | -33.3% |
| Q4 2017 | $148,522,000 | +24.9% | 3,253,501 | +2.7% | 0.01% | 0.0% |
| Q3 2017 | $118,955,000 | -18.8% | 3,167,917 | +3.1% | 0.01% | -14.3% |
| Q2 2017 | $146,538,000 | +12.4% | 3,072,074 | +7.4% | 0.01% | 0.0% |
| Q1 2017 | $130,420,000 | +47.0% | 2,860,092 | +4.1% | 0.01% | +40.0% |
| Q4 2016 | $88,735,000 | -2.8% | 2,747,239 | +3.0% | 0.01% | 0.0% |
| Q3 2016 | $91,272,000 | +4.6% | 2,667,211 | +3.1% | 0.01% | 0.0% |
| Q2 2016 | $87,268,000 | -34.7% | 2,587,221 | +2.6% | 0.01% | -44.4% |
| Q1 2016 | $133,633,000 | -29.5% | 2,522,323 | +2.2% | 0.01% | -30.8% |
| Q4 2015 | $189,582,000 | +92.5% | 2,468,838 | +3.0% | 0.01% | +225.0% |
| Q3 2015 | $98,467,000 | -40.1% | 2,395,770 | +3.2% | 0.00% | -63.6% |
| Q2 2015 | $164,254,000 | -17.5% | 2,322,595 | +3.7% | 0.01% | -21.4% |
| Q1 2015 | $199,072,000 | +5.6% | 2,240,536 | +5.4% | 0.01% | 0.0% |
| Q4 2014 | $188,504,000 | -7.2% | 2,126,133 | +1.5% | 0.01% | -12.5% |
| Q3 2014 | $203,041,000 | +6.3% | 2,094,928 | +0.7% | 0.02% | +6.7% |
| Q2 2014 | $191,080,000 | +39.6% | 2,080,115 | +6.3% | 0.02% | +25.0% |
| Q1 2014 | $136,920,000 | +32.3% | 1,956,277 | +8.6% | 0.01% | +33.3% |
| Q4 2013 | $103,528,000 | +65.9% | 1,800,818 | +38.8% | 0.01% | +50.0% |
| Q3 2013 | $62,398,000 | +180.7% | 1,297,516 | +69.3% | 0.01% | +200.0% |
| Q2 2013 | $22,233,000 | – | 766,620 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |